Altre lingue Unity Biotechnology, Inc.

Azioni

UBX

US91381U2006

Mercato chiuso - Nasdaq Altri mercati azionari 22:00:00 08/07/2024			Variaz. 5gg	Var. 1 gen.
1,33 ^USD	+1,53%		0,00%	-31,09%

14/05	Unity Biotechnology, Inc. riporta i risultati degli utili per il primo trimestre conclusosi il 31 marzo 2024	CI
23/04	Unity Biotechnology, Inc. annuncia l'estensione dello studio clinico ASPIRE di Fase 2b che valuta UBX1325 nella DME	CI

Altre lingue

Sblocca tutte le notizie: sii il primo a essere informato e reagisci prima dei mercati!

Registrazione 100% gratuita

Unity Biotechnology, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	14/05
UNITY Biotechnology, Inc. Reports First Quarter 2024 Financial Results and Business Updates	14/05
UNITY Biotechnology Announces Upcoming Presentations at the ARVO 2024 Annual Meeting	25/04
Unity Biotechnology Adds More Patients, Extends Length of Trial of Prospective Macular Edema Treatment	23/04
UNITY Biotechnology Announces Extension of Phase 2b ASPIRE Clinical Study Evaluating UBX1325 in DME	23/04
Unity Biotechnology, Inc. Announces Extension of Phase 2b ASPIRE Clinical Study Evaluating UBX1325 in DME	23/04
UNITY Biotechnology, Inc. Reports Fourth Quarter and Full Year 2023 Financial Results and Business Updates	15/04
Unity Biotechnology, Inc. Reports Earnings Results for the Fourth Quarter Ended December 31, 2023	15/04
Unity Biotechnology, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	15/04
North American Morning Briefing : Stocks Seen -2-	02/04
North American Morning Briefing : Markets Steady -2-	26/03
New Publication in Nature Medicine Supports Therapeutic Potential of Senolytics to Provide Long-lasting, Disease-modifying Intervention in Vision Loss	06/02
Unity Biotechnology, Inc. Announces New Publication in Nature Medicine Supports Therapeutic Potential of Senolytics to Provide Long-Lasting, Disease-Modifying Intervention in Vision Loss	06/02
UNITY Biotechnology Doses First Patients in Phase 2 ASPIRE Study of UBX1325 in DME	12/12
Unity Biotechnology, Inc. Doses First Patients in Phase 2 Aspire Study of Ubx1325 in DME	12/12
North American Morning Briefing : Stocks Futures -2-	20/11
UNITY Biotechnology, Inc. Reports Third Quarter 2023 Financial Results and Business Updates	13/11
Unity Biotechnology, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	13/11
Sector Update: Health Care Stocks Rising Late Afternoon	10/11
Sector Update: Health Care	10/11

Non ci sono risultati per questa ricerca

Tutte le notizie Raccomandazione analisti Eventi più importanti Insiders Resoconti Comunicati stampa Pubblicazioni ufficiali Altre lingue Idee di trading Articoli MarketScreener Analisi MarketScreener

Altre lingue Unity Biotechnology, Inc.

Azioni

UBX

US91381U2006

Altre lingue

Filtri